These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21521704)

  • 21. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
    Wilcox MH
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linezolid: its role in the treatment of gram-positive, drug-resistant bacterial infections.
    Ament PW; Jamshed N; Horne JP
    Am Fam Physician; 2002 Feb; 65(4):663-70. PubMed ID: 11871684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linezolid, the first oxazolidinone antibacterial agent.
    Leach KL; Brickner SJ; Noe MC; Miller PF
    Ann N Y Acad Sci; 2011 Mar; 1222():49-54. PubMed ID: 21434942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early lactic acidosis associated with linezolid therapy in paediatric patients.
    Ozkaya-Parlakay A; Kara A; Celik M; Ozsurekci Y; Karadag Oncel E; Ceyhan M; Cengiz AB
    Int J Antimicrob Agents; 2014 Oct; 44(4):334-6. PubMed ID: 25182713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of linezolid in 16 infants and children in Japan.
    Shinjoh M; Iketani O; Watanabe K; Shimojima N; Kudo M; Yamagishi H; Shimada H; Sugita K; Takahashi T; Mori T; Hasegawa N; Iwata S
    J Infect Chemother; 2012 Aug; 18(4):591-6. PubMed ID: 22460827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linezolid for the treatment of drug-resistant infections.
    Herrmann DJ; Peppard WJ; Ledeboer NA; Theesfeld ML; Weigelt JA; Buechel BJ
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):825-48. PubMed ID: 19053895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
    Wilcox M; Nathwani D; Dryden M
    J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class.
    Nilius AM
    Curr Opin Investig Drugs; 2003 Feb; 4(2):149-55. PubMed ID: 12669374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skin.
    Schweiger ES; Scheinfeld NS; Tischler HR; Weinberg JM
    J Drugs Dermatol; 2003 Aug; 2(4):378-83. PubMed ID: 12884459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging therapies for serious gram-positive bacterial infections: a focus on linezolid.
    Plouffe JF
    Clin Infect Dis; 2000 Sep; 31 Suppl 4():S144-9. PubMed ID: 11017864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
    Beibei L; Yun C; Mengli C; Nan B; Xuhong Y; Rui W
    Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hematologic effects of linezolid in young children.
    Meissner HC; Townsend T; Wenman W; Kaplan SL; Morfin MR; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S186-92. PubMed ID: 14520145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and tolerance of linezolid for meticillin-resistant Staphylococcus aureus mediastinitis in paediatric patients.
    Kosaka T; Kokufu T; Shime N; Sugioka N; Kato R; Hamaoka K; Fujita N
    Int J Antimicrob Agents; 2009 Apr; 33(4):368-70. PubMed ID: 19097868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quinupristin-dalfopristin and linezolid: evidence and opinion.
    Eliopoulos GM
    Clin Infect Dis; 2003 Feb; 36(4):473-81. PubMed ID: 12567306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study.
    Wilcox MH; Tack KJ; Bouza E; Herr DL; Ruf BR; Ijzerman MM; Croos-Dabrera RV; Kunkel MJ; Knirsch C
    Clin Infect Dis; 2009 Jan; 48(2):203-12. PubMed ID: 19072714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
    Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
    J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.
    Birmingham MC; Rayner CR; Meagher AK; Flavin SM; Batts DH; Schentag JJ
    Clin Infect Dis; 2003 Jan; 36(2):159-68. PubMed ID: 12522747
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
    Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.